In humans, Hodgkin’s lymphoma (HL) has among the highest response rates to ICB therapy (greater than 70%), but HL cells frequently downregulate MHCI expression, which indicates that CD4+ T cells may play an important role in generating tumor immunity in these patients (54). The gene discussed is CD4; the disease is neoplasm.